Arcellx, Inc.
ACLX
Rank in Stocks
#2777
Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to... Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multiple myeloma (MM). Beyond their lead candidate, Arcellx is also advancing ACLX-001, an immunotherapy composed of ARC-T cells and bi-valent SparX proteins engineered to combat r/r MM by targeting BCMA. Their development efforts extend to ACLX-002 and ACLX-003, designed to address relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), alongside a broader portfolio of additional AML/MDS candidates and programs focused on solid tumors. The company, headquartered in Gaithersburg, Maryland, was established in 2014. It operated as Encarta Therapeutics, Inc. before adopting its current name, Arcellx, Inc., in January 2016.
Share Price
$115.07
Last synced: 2026-05-15
Market Cap
$6.73B
Change (1 day)
0.00%
Change (1 year)
32.61%
Country
US
Trade Arcellx, Inc. (ACLX)
Category
Healthcare
P/B ratio for Arcellx, Inc. (ACLX)
P/B ratio as of October 2026 TTM: 16.10
According to Arcellx, Inc. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 16.10. At the end of 2023 the company had a P/B ratio of 5.50.
P/B ratio history for Arcellx, Inc. from 2018 to 2026
P/B ratio at the end of each year
| Year | P/B Ratio | Change |
|---|---|---|
| 2026 (TTM) | 16.10 | 78.33% |
| 2024 | 9.03 | 64.37% |
| 2023 | 5.50 | -17.57% |
| 2022 | 6.67 | 32.34% |
| 2021 | 5.04 | -30.41% |
| 2020 | 7.24 | -140.56% |
| 2019 | -17.85 | -9,055.54% |
| 2018 | 0.20 | 0.00% |
P/B ratio for similar companies or competitors
| Company | P/B Ratio | P/B Ratio Difference | Country |
|---|---|---|---|
| 6.251 | -61.18% |
US
|
|
| 13.2547 | -17.69% |
US
|
|
| 4.208 | -73.87% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -61.61% |
NL
|
